{
    "clinical_study": {
        "@rank": "11517", 
        "arm_group": {
            "arm_group_label": "Ibuprofen 600 mg Immediate Release/Extended Release Caplet", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "A self-selection and actual use trial to evaluate the extent to which consumers will\n      appropriately select and use the 600 mg immediate release/extended release caplets and\n      comply with dosing instructions."
        }, 
        "brief_title": "Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Analgesia", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  at least 12 years of age\n\n          -  use of at least 5 doses per month of over-the-counter pain relievers over the past 3\n             months\n\n          -  provide written informed consent (subjects 12-<18 years of age provide a written\n             assent and parent/guardian will provide written informed consent)\n\n          -  capable of and willing to swallow the study medication\n\n        Exclusion Criteria:\n\n          -  participated in other research studies in the last 6 months\n\n          -  they or someone else in their household work for a pharmaceutical company, is a\n             relative of study site personnel involved with the study, or an immediate family\n             member is already enrolled in the study\n\n          -  have a history of known allergies to ibuprofen, aspirin, or other NSAIDs\n\n          -  have a history of heart surgery in the last 60 days or planned heart surgery in the\n             next 60 days\n\n          -  female subjects are pregnant or breast feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "712", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01789606", 
            "org_study_id": "B4371008", 
            "secondary_id": "AK-10-11"
        }, 
        "intervention": {
            "arm_group_label": "Ibuprofen 600 mg Immediate Release/Extended Release Caplet", 
            "description": "Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.", 
            "intervention_name": "Ibuprofen 600 mg Immediate Release/Extended Release Caplet", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ibuprofen"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Self-selection and actual use/compliance trial.", 
        "lastchanged_date": "August 22, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B4371008&StudyName=Self-Selection%20and%20Actual%20Use%20Trial%20of%20Ibuprofen%20600%20mg%20Immediate%20Release/Extended%20Caplet"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92801"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yorba Linda", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92886"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Griffin", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30224"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66209"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21228"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Blaine", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55434"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Elk River", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55330"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis Park", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55426"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64111"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Savannah", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64485"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87104"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taos", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87571"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ogden", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84401"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84121"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Jordan", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84088"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpelier", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23192"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kenmore", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98028"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Snohomish", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98290"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Ibuprofen 600 mg Immediate Release/Extended Release (IR/ER) Caplet Self-Selection, Safety and Compliance Study", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Among those who select the 600 mg IR/ER product, the percentage of subjects who report their typical duration of pain, if left untreated, to be greater than or equal to 6 hours, will be considered to have corectly self-selected. Likewise, among those who do not select the 600 mg product who report their typical duration of pain, if left untreated, to be less than 6 hours will be considered to have correctly de-selected the IR/ER product.", 
                "measure": "Self-Selection Arm: Percentage of participants who either correctly select to use or correctly de-select not to use the 600 mg IR/ER product, based on typical duration of pain.", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Excessive use of the product is defined as:\n(1) Using the product for more than 10 days (not necessarily consecutive) during the study and having an average daily dose greater than 1600 mg OR (2) Using the product for 10 days or less during the study, taking more than 20 caplets and having an average daily dose greater than 1600 mg.", 
                "measure": "Compliance Arm: Percentage of participants who use the product for more than 10 days (not necessarily consecutive) during the study and have an average daily dose of greater than 1600 mg.", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Excessive use of the product is defined as:\n(1) Using the product for more than 10 days (not necessarily consecutive) during the study and having an average daily dose greater than 1600 mg OR (2) Using the product for 10 days or less during the study, taking more than 20 caplets and having an average daily dose greater than 1600 mg.", 
                "measure": "Compliance Arm: Percentage of participants who use the product for 10 days or less during the study, take more than 20 caplets and have an average daily dose of greater than 1600 mg.", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01789606"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Dosing patterns among subjects who use the product excessively.", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Dosing patterns among subjects who are inappropriate self-selectors.", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Dosing patterns related to exceeding 1200 mg/day.", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Dosing paterns related to exceeding 600 mg/dose.", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Average daily dose (within subject).", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Maximum daily dose.", 
                "safety_issue": "No", 
                "time_frame": "30 days"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}